Breast Cancer

Manas Dubey: SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) Clinical Trials

Manas Dubey, Medical Oncologist and Hemat-Oncologist at Kamla Nehru Memorial Hospital, posted on X:

“SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial), two landmark clinical trials.
Results:
12-year DFS rates –
Tamoxifen alone (67.0%), Tamoxifen + Ovarian Function Suppression (OFS) (70.5%), and Exemestane + OFS (73.5%).”

Manas Dubey: SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) Clinical Trials

More posts featuring Breast Cancer.

Breast Cancer cancer Manas Dubey OncoDaily Oncology SOFT TEXT